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Abstract
Introduction: Hypolipidaemic agents were found to affect plasma adipokine levels, but no previous study has investigated whether this 
effect is sex-dependent.
Materials and methods: We retrospectively analysed 61 patients participating in our previous studies, who because of isolated hyper-
cholesterolaemia were treated with simvastatin (40 mg daily), ezetimibe (10 mg daily) or simvastatin (40 mg daily) plus ezetimibe (10 mg 
daily). Plasma levels of leptin, adiponectin, visfatin, tumour necrosis factor-a (TNF-a), free fatty acids (FFA), and high-sensitivity C-reactive 
protein (hsCRP) were assessed separately for men and women before and after 30 days of treatment.
Results: At baseline, plasma levels of adiponectin and leptin were lower, while plasma levels of TNF-a were higher in men than in women. 
Administration of simvastatin and statin/ezetimibe combination for 30 days reduced plasma levels of hsCRP, FFA, leptin, visfatin, and 
TNF-a but increased plasma levels of adiponectin, while the effect of ezetimibe was much more limited. The effect of simvastatin and 
ezetimibe, administered alone or in combination, on plasma hsCRP, FFA, leptin, adiponectin, visfatin, and TNF-a did not differ between 
men and women. Irrespectively of sex, the changes in plasma adipokines and systemic-anti-inflammatory effects were more expressed 
in simvastatin- than in ezetimibe-treated patients and were strongest when both these agents were administered together. 
Conclusions: Our results show that sex differences do not determine the effect of hypolipidaemic agents on adipose tissue and low-grade 
inflammation. (Endokrynol Pol 2015; 66 (2): 114–120)
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Abstrakt
Wstęp: Chociaż wykazano związek pomiędzy stosowaniem terapii hipolipemicznej a zmianami stężenia adipokin, nie oceniano czy 
wpływ ten zależy od płci pacjenta.
Materiał i metody: W badaniu dokonano retrospektywnej analizy wyników 61 pacjentów uczestniczących w poprzednich badaniach 
autorów, którzy z racji hipercholesterolemii byli leczeni simwastatyną (40 mg dziennie), ezetimibem (10 mg dziennie) oraz terapią sko-
jarzoną (w powyższych dawkach). Stężenie leptyny, adiponektyny, wisfatyny, czynnika martwicy nowotworów-a (TNF-a), wolnych 
kwasów tłuszczowych (FFA) oraz białka C-reaktywnego (hsCRP) oceniano oddzielnie dla kobiet i mężczyzn przed i po 30 dniach leczenia.
Wyniki: W warunkach wyjściowych stężenie leptyny i adiponektyny w osoczu było wyższe dla kobiet, zaś TNF-a u mężczyzn. Podawanie 
simwastatyny lub terapii skojarzonej przez 30 dni zmniejszało stężenie w osoczu hsCRP, FFA, leptyny, wisfatyny, TNF-a, jak również 
podwyższało stężenie adiponektyny, podczas gdy wpływ ezetimibu był ograniczony. Wpływ simwastatyny i ezetimibu, podawanych 
oddzielnie lub w terapii skojarzonej, na stężenie hsCRP, FFA, leptyny, adiponektyny, wisfatyny oraz TNF-a nie różnił się pomiędzy ko-
bietami i mężczyznami. Niezależnie od płci pacjenta, zmiany stężenia badanych adipokin i nasilenia układowego stanu zapalnego były 
bardziej wyrażone w grupie leczonej simwastatyną niż ezetimibem i najwyraźniej zaznaczone w grupie stosującej terapię skojarzoną. 
Wnioski: Wyniki badania wskazują, iż płeć pacjenta nie warunkuje siły działania ocenianych leków hipolipemicznych na tkankę tłusz-
czową i układowy stan zapalny. (Endokrynol Pol 2015; 66 (2): 114–120)
Słowa kluczowe: płeć; simwastatyna; ezetimib; hypercholesterolemia; leptyna; adiponektyna; wisfatyna; czynnik martwicy nowotworów-a 
(TNF-a)
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current law of Poland.
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Abbreviations
CRP — C-reactive protein
FFA — free fatty acids
HDL — high-density lipoprotein
HMG-CoA — 3-hydroxy-3-methylglutaryl coenzyme A
HOMA-IR — the homeostatic model assessment of 
insulin resistance ratio
hsCRP — high-sensitivity C-reactive protein
LDL — low-density lipoprotein
TNF-a — tumour necrosis factor-a
Introduction
Coronary artery disease is the leading cause of car-
diovascular morbidity and mortality in both men and 
women [1]. The absolute numbers of women living with 
and dying of coronary artery disease and stroke exceed 
those of men, as does the number of hospital discharges 
for heart failure and stroke [2]. Despite this fact, several 
lines of evidence suggest that coronary artery disease 
is treated less aggressively in women than in men. Hy-
polipidaemic agents, particularly 3-hydroxy-3-methyl-
glutaryl-CoA (HMC-CoA) reductase inhibitors (statins), 
are among the most important agents in the contem-
porary therapy of patients with this disorder. Beyond 
lowering lipid levels, the clinical benefits associated 
with hypolipidaemic agents may partially result from 
their extralipid, so-called pleiotropic effects. Very little 
is known about differences in the strength of action of 
lipid-lowering agents between men and women. The 
results of the Action to Control Cardiovascular Risk 
in Diabetes Lipid (ACCORD Lipid) trial, comparing 
fenofibrate/simvastatin combination therapy with 
simvastatin administered alone in patients with type 
2 diabetes, showed additional benefits associated with 
adding fenofibrate to a HMG-CoA reductase inhibitor 
exclusively in men [3]. Men had a 16% lower primary 
event rate on fenofibrate, whereas women had a 38% 
greater primary event rate on fenofibrate.
The various strengths of action of hypolipidaemic 
agents in men and women may be explained by sex-
dependent differences in either their lipid-lowering po-
tential and/or pleiotropic effects. The latter may include 
their effect on adipose tissue secretory function. This 
tissue is a highly active metabolic and endocrine organ 
secreting a range of bioactive peptides with both local 
and distant actions, known as ‘adipokines’ or ‘adipose 
tissue hormones, being specific fat-related hormones 
that are involved in regulating energy homeostasis, car-
bohydrate and lipid metabolism, and the function of the 
cardiovascular system [4–6]. Adipose tissue is characterised 
by gender differences in body distribution and different 
production of adipokines [4–6]. Therefore, the question 
of how hypolipidaemic agents affect the hormonal func-
tion of human adipose tissue in both sexes requires better 
understanding. The aim of our study was to compare 
the effects of 30-day treatment with two hypolipidaemic 
agents, atorvastatin and ezetimibe, administered alone or 
in combination, on plasma adipokine levels in men and 
women with isolated hypercholesterolaemia, participating 
in our previous studies [7–9]. The results of one study were 
not taken into consideration because of a longer period of 
treatment [10]. Leptin, adiponectin, visfatin, and TNF-a 
were chosen among different adipokines because 
they are major products of adipose tissue, playing 
a variety of roles in atherosclerotic plaque development 
and its clinical sequelae. Their abnormal production 
contributes to the development of diabetes and insulin 
resistance as well as atherosclerosis and its complications 
[6, 11–13].
Material and methods
We retrospectively analysed patients included in our 
previous studies [7–9]. The study was performed ac-
cording to the Declaration of Helsinki. All individuals 
participating in the original studies were fully informed 
of the purpose and the possible risks. All participants 
provided written consent as approved by the ethics 
committee of the Medical University of Silesia. The study 
population consisted of men and women (35–65 years 
old) with isolated hypercholesterolaemia, defined as total 
plasma cholesterol above 200 mg/dL, LDL cholesterol 
above 130 mg/dL, and triglycerides below 150 mg/dL, 
despite following the Therapeutic Lifestyle Changes diet 
for at least three months before the study onset, and who 
during the study were treated with simvastatin (n = 22) 
[7], ezetimibe (n = 21) [8], or combination therapy (n = 
18) [9]. The exclusion criteria were as follows: any acute 
and chronic inflammatory processes, untreated stage 2 
or 3 hypertension (according to the 2003 European So-
ciety of Hypertension–European Society of Cardiology 
guidelines), symptomatic congestive heart failure, dia-
betes, autoimmune disorders, thyroid diseases, chronic 
pancreatitis, impaired renal or hepatic function, body 
mass index above 35 kg/m2, and poor patient compliance. 
No patient had been treated with other hypolipidaemic 
drugs within three months before the study, or with 
drugs known to interfere with statins or ezetimibe.
Simvastatin (40 mg), ezetimibe (10 mg), or simvastatin 
(40 mg) together with ezetimibe (10 mg) were adminis-
tered once daily at bedtime for 30 days, and no changes 
in medication dosage were allowed throughout the study. 
Throughout the study the participants complied with 
lifestyle modifications, the goals of which were a reduc-
tion in weight of 7% or more if necessary, total fat intake 
< 30% of total energy intake, saturated fat intake < 7% of 
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energy consumed, cholesterol intake < 200 mg per day, an 
increase in fibre intake to 15 g per 1000 kcal, and moderate-
to-vigorous exercise for at least 30 minutes per day.
The samples were collected before therapy started 
and after 30 days of therapy. Venous blood samples 
were drawn from the antecubital vein in a quiet, 
temperature-controlled room (24–25°C) in constant 
daily hours (between 8:00 and 9:00 a.m.) at least 
12 hours after the last meal. All assays were carried 
out in duplicate, and mean values are presented. Total 
cholesterol, high-density lipoprotein (HDL) cholesterol, 
LDL cholesterol, triglycerides, glucose, and insulin 
were assessed by routine laboratory techniques (bi-
oMerieux France; Incstar Corporation, Stillwater, MN, 
USA; Beckman, Palo Alto, CA, USA; Linco Research 
Inc, St Charles, MO, USA). LDL levels were measured 
directly. The homeostasis model of insulin resistance 
(HOMA-IR) index was calculated as [fasting serum 
glucose (mg/dL) × fasting serum insulin (µU/mL)/405], 
with lower values indicating a higher degree of insulin 
sensitivity. Total non-esterified free fatty acids (FFA) 
were determined by an enzymatic assay using reagents 
from Alpha Laboratories (Eastleigh, Hants, UK). Plasma 
levels of CRP were measured using a high-sensitivity 
monoclonal antibody assay (hsCRP) (MP Biomedicals, 
Orangeburg, NY). Plasma levels of leptin, adiponectin, 
visfatin, and TNF-a were measured with commercial 
enzyme-linked immunosorbent assay kits obtained 
from TECOmedical Group (Sissach, Switherland), 
Phoenix Pharmaceuticals (Burlingame, CA) and R&D 
Systems (McKinley Place N.E. Minneapolis, MN). The 
minimum detectable levels for the assessed parameters 
were: 0.1 mg/L, 7.8 pg/mL, 0.246 ng/mL, 6.1 pg/mL, and 
1.6 pg/mL, respectively, for hsCRP, leptin, adiponectin, 
visfatin, and TNF-a. The intra- and inter-assay coef-
ficients of variation for the assessed markers were less 
than 5.5 and 8.7%, respectively.
The Shapiro-Wilk test was used to assess the distribu-
tion of variables. In the case of variables with non-normal 
distribution (triglycerides, HOMA-IR, hsCRP, FFA, and 
adipokines), log transformation was used to fit a normal 
distribution curve. Comparisons between the groups were 
made by the t test for independent samples. The differ-
ences between the means of variables within the same 
treatment group were analyzed with Student’s paired 
t-test. Kendall’s t test was used to evaluate the relationship 
between metabolic variables and inflammatory mediators. 
A p-value less than 0.05 was considered significant.
Results
At baseline, the populations of women and men were 
comparable with respect to age, body weight, medical 
background, and plasma lipids (Table I). Both popula-
Table I. Baseline characteristics of the participants
Tabela I. Wyjściowa charakterystyka pacjentów
Together Women Men
Number of patients 61 26 35
Age [years; mean (SD)] 52.1 (1.9) 51.7 (2.4) 52.3 (2.1)
Smokers (%) 25 23 26
Body mass index [kg/m2; mean (SD)] 26.6 (2.5) 26.0 (2.9) 27.0 (2.7)
Waist circumference [cm; mean (SD)] 96 (4) 92 (5) 99 (4)**
Intima-media thickness [mm; mean (SD)] 0.96 (0.12) 0.94 (0.18) 0.97 (0.15)
Total cholesterol [mg/dL; mean (SD)] 252 (12) 245 (16) 257 (14)
LDL cholesterol [mg/dL; mean (SD)] 180 (10) 173 (15) 185 (13)
HDL cholesterol [mg/dL; mean (SD)] 47 (4) 49 (7) 46 (5)
Triglycerides [mg/dL; mean (SD)] 124 (10) 117 (18) 129 (16)
Glucose [mg/dL; mean (SD)] 95 (5) 94 (6) 95 (5)
HOMA-IR [mean (SD)] 2.8 (0.7) 2.8 (0.9) 2.9 (0.8)
hsCRP [mg/L; mean (SD)] 3.4 (0.5) 3.5 (0.7) 3.4 (0.7)
FFA [µmol/L; mean (SD)] 379 (43) 371 (50) 385 (48)
Leptin [ng/mL; mean (SD)] 24.7 (5.1) 34.6 (3.5) 17.3 (2.3)***
Adiponectin [mg/L; mean (SD)] 5.6 (1.0) 6.9 (0.9) 4.6 (0.8)***
Visfatin [ng/mL; mean (SD)] 21.3 (2.4) 22.1 (2.7) 20.7 (2.5)
TNF-a [pg/mL; mean (SD)] 15.9 (2.3) 13.1 (2.9) 18.0 (2.8)**
**p < 0.01; ***p < 0.001 vs. women
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tions differed in waist circumference. Plasma levels of 
adiponectin and leptin were lower, while plasma levels 
of TNF-a higher in men than in women. No differences 
between men and women were observed in HOMA-IR, 
FFA, hsCRP, and visfatin.
Irrespectively of gender, all treatment options de-
creased total and LDL cholesterol but did not produce 
any significant effect on HDL cholesterol and triglyc-
erides (Tables II–IV). In both men and women, simvas-
tatin (Table II) and simvastatin/ezetimibe combination 
therapy (Table IV) reduced plasma levels of hsCRP, 
FFA, leptin, and TNF-a but increased plasma levels of 
adiponectin. Simvastatin administered together with 
ezetimibe, but not administered alone, to hypercholes-
terolemia women and men reduced additionally plasma 
visfatin. Irrespectively of sex, ezetimibe administered 
for 30 days only tended to reduce plasma levels of 
hsCRP (p = 0.094 for women; p = 0.098 for men) and 
did not affect circulating levels of FFA, leptin, adiponec-
tin, visfatin, and TNF-a (Table III).
The effect of simvastatin and ezetimibe, admin-
istered alone or in combination, on plasma hsCRP, 
FFA, leptin, adiponectin, visfatin, and TNF-a did not 
differ between men and women (Tables I–III). Irre-
spectively of sex, the effect of simvastatin/ezetimibe 
combination therapy on plasma lipids, hsCRP, FFA, and 
all adipokines was stronger than that of simvastatin 
or ezetimibe alone, while the effect of simvastatin on 
hsCRP, FFA, leptin, adiponectin, and TNF-a, but not 
on plasma lipids and visfatin, was stronger than that 
of ezetimibe (data not shown). 
At baseline, in both sexes, plasma adiponectin levels 
correlated negatively with total cholesterol, LDL choles-
terol, as well as with HOMA-IR, FFA, and hsCRP (men: 
r values between –0.35 [p < 0.01] and –0.59 [p < 0.001]; 
women: r values between –0.32 [p < 0.05] and –0.55 
[p < 0.001]). There were positive correlations between 
plasma levels of the remaining adipokines assessed by 
our team and total cholesterol, LDL cholesterol, HOMA-
IR, FFA, and hsCRP (men: r values between 0.32 [p < 0.05] 
and 0.60 [p < 0.001]; women: r values between 0.29 
[p < 0.05] and 0.58 [p < 0.001]). 
Irrespectively of gender, the effect of hypolipi-
daemic treatment on leptin, adiponectin, visfatin, 
and TNF-a correlated with the reduction in hsCRP 
(men: r values between 0.42 [p < 0.001] and 0.58 
[p < 0.001]; women: r values between 0.40 [p < 0.001] 
and 0 .57 [p < 0.001]) ,  FFA (men:  r  values 
between 0.43 [p < 0.001] and 0.56 [p < 0.001]; 
women: r values between 0.42 [p < 0.001] and 0.55 
Table II. The effect of 30-day simvastatin treatment on plasma 
lipids, glucose metabolism markers and circulating levels 
of high sensitivity C-reactive protein, free fatty acids, and 
the investigated adipokines in hypercholesterolaemic men 
and women
Tabela II. Wpływ 30-dniowego stosowania simwastatyny 
na stężenie lipidów, markery gospodarki węglowodanowej 
oraz stężenie białka C-reaktywnego, wolnych kwasów 
tłuszczowych i ocenianych adipokin u kobiet i mężczyzn 
z izolowaną hipercholesterolemią
Women 
(n = 9)
Men 
(n = 13)
DTotal cholesterol [%; mean (SD)] –28 (7)*** –23 (5)***
DLDL cholesterol [%; mean (SD)] –31 (8)*** –28 (7)***
DHDL cholesterol [%; mean (SD)] 2 (4) 6 (5)
DTriglycerides [%; mean (SD)] –11 (8) –8 (8)
DGlucose [%; mean (SD)] 2 (4) 2 (3)
DHOMA-IR [%; mean (SD)] 4 (8) 4 (6)
DhsCRP [%; mean (SD)] –23 (5)** –26 (6)**
DFFA [%; mean (SD)] –19 (4)* –19 (3)*
DLeptin [%; mean (SD)] –26 (7)* –29 (6)*
DAdiponectin [%; mean (SD)] 29 (7)* 32 (5)*
DVisfatin [%; mean (SD)] –18 (5) –18 (4)
DTNF-a [%; mean (SD)] –20 (7)* –23 (5)*
The data show percentage changes from the respective baseline value.  
*p < 0.05; **p < 0.01; ***p < 0.001 post-treatment vs. baseline value 
Table III. The effect of 30-day ezetimibe treatment on plasma 
lipids, glucose metabolism markers and circulating levels 
of high sensitivity C-reactive protein, free fatty acids, and 
the investigated adipokines in hypercholesterolaemic men 
and women
Tabela III. Wpływ 30-dniowego stosowania ezetimibu na 
stężenie lipidów, markery gospodarki węglowodanowej 
oraz stężenie białka C-reaktywnego, wolnych kwasów 
tłuszczowych i ocenianych adipokin u kobiet i mężczyzn 
z izolowaną hipercholesterolemią
Women 
(n = 9)
Men 
(n = 12)
DTotal cholesterol [%; mean (SD)] –24 (7)*** –21 (6)***
DLDL cholesterol [%; mean (SD)] –28 (8)*** –25 (6)***
DHDL cholesterol [%; mean (SD)] 4 (4) 0 (6)
DTriglycerides [%; mean (SD)] –9 (12) –9 (10)
DGlucose [%; mean (SD)] –2 (4) –2 (4)
DHOMA-IR [%; mean (SD)] –18 (6) –15 (7)
DhsCRP [%; mean (SD)] –17 (4) –19 (5)
DFFA [%; mean (SD)] –16 (4) –15 (4)
DLeptin [%; mean (SD)] –12 (5) –15 (3)
DAdiponectin [%; mean (SD)] 3 (2) 4 (2)
DVisfatin [%; mean (SD)] –17 (5) –14 (4)
DTNF-a [%; mean (SD)] –12 (5) –13 (4)
The data show percentage changes from the respective baseline value.  
***p < 0.001 post-treatment vs. baseline value
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[p < 0.001]), and in the case of ezetimibe or simvastatin/ 
/ezetimibe combination therapy with HOMA-IR (men: 
r values between 0.35 [p < 0.01] and 0.49 [p < 0.001]; 
women: r values between 0.37 [p < 0.01] and 0.47 
[p < 0.001]). No correlation was observed between hy-
polipidaemic treatment on plasma adipokine levels and 
the effects of this treatment on plasma lipids in either 
men or women. In both men and women, the effect 
of simvastatin, ezetimibe, and simvastatin/ezetimibe 
combination therapy on plasma adipokines correlated 
with the reduction in TNF-a (men: r values between 
0.30 [p < 0.05] and 0.50 [p < 0.001]; women: r values 
between 0.29 [p < 0.05] and 0.47 [p < 0.001]). 
Discussion
In this study, we have found for the first time that the 
effect of treatment with an HMG-CoA reductase inhibi-
tor and ezetimibe on plasma lipid levels and on adipose 
tissue products does not depend on sex. Strict inclusion 
criteria and similar clinical and laboratory characteristics 
of both the men and women included in the analysis 
minimised the possibility that the obtained findings 
resulted from the impact of other concurrent diseases 
or concomitant therapies.
Expectedly [14, 15], baseline levels of leptin and 
adiponectin were higher in the women than in the 
men, and these sex differences probably result from 
the higher fat mass in women, particularly the presence 
of more subcutaneous adipose tissue, being the most 
important source of both adipokines, and from differ-
ences in oestrogen or androgen concentrations. The 
opposite relationship was found for TNF-a, produced 
in adipose tissue predominantly by inflammatory 
cells (mainly macrophages) [4–6], circulating levels of 
which were, like in another study [16], higher in men. 
Interestingly, lymphocyte release of proinflammatory 
cytokines is sex-dependent and higher in men than 
women [Krysiak et al., unpublished observations], and 
if adipose tissue macrophages behave in a similar way, 
this finding may partially explain the obtained results.
Interestingly, we have not found sex-dependent 
differences in baseline concentrations of hsCRP, con-
sidered a highly sensitive marker of low-grade vas-
cular inflammation and a protein directly involved in 
atherogenesis [17]. Studies conducted hitherto have 
provided conflicting results; the obtained results are 
in line with the findings of some [18, 19] but not other 
[16] research groups. The authors of the last study [16] 
explained higher hsCRP levels by a higher percentage 
of adipose tissue in women than in men. It is possible 
that the similar hsCRP levels observed by our research 
team and found previously by other authors [18, 19] 
reflect either smaller differences in fat content between 
men and women participating in these studies or may 
result from higher levels of proinflammatory cytokines 
stimulating systemic low-grade inflammation. Such 
a role may be played by TNF-a, and possibly also by 
interleukin-6, being the most important stimulator of 
CRP production [20]. These cytokines are produced 
by inflammatory cells, the function of which, as men-
tioned, is more impaired in hypercholesterolaemic 
men than women, while the production of TNF-a and 
interleukin-6 is inhibited by simvastatin and ezetimibe, 
administered alone or in combination [21, 22].
Despite sex differences in body fat distribution and 
systemic sex hormone concentrations, gender had a lim-
ited influence on response to lipid-lowering therapies, 
assessed by percentage changes in circulating levels of 
the assessed variables. We can only try to explain these 
findings. Hypolipidaemic agents directly affect adipose 
tissue adipokine release [23, 24], and therefore their ac-
tion at the level of adipocytes and other types of cells 
present in adipose tissue may not differ between both 
sexes. It should be underlined that both investigated 
drugs had a neutral impact on body weight (data not 
shown), and so treatment-induced changes in plasma 
adipokines reflect rather alternation in secretory func-
tion of these cells than a reduction in fat content. Alter-
Table IV. The effect of 30-day simvastatin/ezetimibe combina- 
tion therapy on plasma lipids, glucose metabolism markers 
and circulating levels of high sensitivity C-reactive 
protein, free fatty acids, and the investigated adipokines in 
hypercholesterolaemic men and women
Tabela IV. Wpływ 30-dniowego stosowania simwastatyny 
wraz z ezetimibem na stężenie lipidów, markery gospodarki 
węglowodanowej oraz stężenie białka C-reaktywnego, 
wolnych kwasów tłuszczowych i ocenianych adipokin 
u kobiet i mężczyzn z izolowaną hipercholesterolemią
Women 
(n = 8)
Men 
(n = 10)
DTotal cholesterol [%; mean (SD)] –37 (8)*** –40 (8)***
DLDL cholesterol [%; mean (SD)] –44 (10)*** –48 (9)***
DHDL cholesterol [%; mean (SD)] 14 (8) 8 (4)
DTriglycerides [%; mean (SD)] –10 (12) –12 (14)
DGlucose [%; mean (SD)] –2 (3) –2 (3)
DHOMA–IR [%; mean (SD)] –22 (–15) –15 (–11)
DhsCRP [%; mean (SD)] –40 (8)*** –45 (9)***
DFFA [%; mean (SD)] –28 (6)** –24 (5)**
DLeptin [%; mean (SD)] –40 (10)*** –42 (9)***
DAdiponectin [%; mean (SD)] –47 (16)*** –57 (11)***
DVisfatin [%; mean (SD)] –27 (7)* –32 (5)**
DTNF–a [%; mean (SD)] –38 (10)*** –34 (7)
*** The data show percentage changes from the respective baseline value.  
*p < 0.05; **p < 0.01; ***p < 0.01 post-treatment vs. baseline value
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natively, their indirect effect mediated by sex hormones 
may be similar. Interestingly, we previously observed 
that both statin [25, 26] and ezetimibe [Krysiak et al., 
unpublished observations] therapy reduced androgen 
levels in both men and women, and their similar effect 
on oestrogen production cannot be excluded. 
Analyses of changes in plasma lipids by sex sub-
groups have demonstrated that the male and female 
patients responded similarly to the treatment. This 
finding is in contrast with the results of some authors 
[27, 28], who observed that ezetimibe/statin combina-
tion therapy and statin monotherapy enabled achieve-
ment of significantly greater reduction of total and LDL 
cholesterol levels in male patients than female patients. 
These contrasting results may, in our opinion, be at-
tributed to similar baseline concentrations of total and 
LDL cholesterol in our study, whereas in the observa-
tions of other authors, cholesterol levels were higher 
in women than men.
Irrespectively of gender, the effect of ezetimibe, 
administered alone or in combination with simvastatin, 
on plasma TNF-a, leptin, adiponectin, and visfatin was 
lipid-independent but correlated with drug-induced 
improvement in insulin sensitivity. This improvement 
is likely to be a consequence of a similar reduction in 
plasma levels of FFA and TNF-a, high levels of which 
play an important role in the development of insulin 
resistance [29, 30]. In the case of TNF-a, but not FFA, 
similar percentage changes in plasma levels contrasted 
with statistically significant differences in baseline 
plasma levels. Interestingly, in the men and women 
treated exclusively with simvastatin, the effect on 
adipokines correlated with the changes in FFA but not 
with the changes in HOMA-IR. This finding is probably 
a consequence of the fact that the impact of simvastatin 
on FFA and TNF-a is counterbalanced by an inhibitory 
effect of statin-induced inhibition of protein prenylation 
on glucose transporter 4 activity [31]. This transporter, 
found primarily in adipose tissue and striated muscle, 
is responsible for insulin-regulated glucose transport 
into the cell [32].
There are some important limitations of this study, 
the most important of which are the small number of 
participants and the short period of treatment. Sec-
ondly, although the original studies were prospective 
in nature, this study was a retrospective analysis of the 
obtained results. Finally, the assessment of adipokines 
in the plasma does not precisely reflect their release 
by different types of adipose tissue, and therefore we 
cannot totally rule out some sex-dependent differences 
in the action of both drugs at the level of local adipose 
tissue depots.
Conclusions
The obtained results indicate that the effect of simv-
astatin, ezetimibe, and their combination on plasma 
adipokine levels and low-grade systemic inflammation 
is similar in men and in women. Further research in 
larger populations is needed to confirm our results.
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